Investigational Drug Information for HQP1351
✉ Email this page to a colleague
What is the drug development status for HQP1351?
HQP1351 is an investigational drug.
There have been 9 clinical trials for HQP1351.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2022.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, and Leukemia. The leading clinical trial sponsors are Ascentage Pharma Group Inc., HealthQuest Pharma Inc., and Shenzhen Second People's Hospital.
There are two US patents protecting this investigational drug and twenty-nine international patents.
Summary for HQP1351
| US Patents | 2 |
| International Patents | 29 |
| US Patent Applications | 18 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 1 (2022-07-01) |
| Vendors | 53 |
Recent Clinical Trials for HQP1351
| Title | Sponsor | Phase |
|---|---|---|
| Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | Shenzhen Second People's Hospital | Phase 3 |
| Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT | Guangdong Second Provincial General Hospital | Phase 2 |
| Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT | Nanfang Hospital of Southern Medical University | Phase 2 |
Clinical Trial Summary for HQP1351
Top disease conditions for HQP1351
Top clinical trial sponsors for HQP1351
US Patents for HQP1351
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| HQP1351 | ⤷ Sign Up | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (Guangzhou, Guangdong, CN) | ⤷ Sign Up |
| HQP1351 | ⤷ Sign Up | Proteolysis targeting chimera compounds and methods of preparing and using same | Yale University (New Haven, CT) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for HQP1351
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| HQP1351 | Australia | AU2011274192 | 2030-07-01 | ⤷ Sign Up |
| HQP1351 | Canada | CA2804347 | 2030-07-01 | ⤷ Sign Up |
| HQP1351 | China | CN101885722 | 2030-07-01 | ⤷ Sign Up |
| HQP1351 | China | CN103124730 | 2030-07-01 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
